In this article

Beyond Meat “Beyond Burger” patties made from plant-based substitutes for meat products sit on a shelf for sale on November 15, 2019 in New York City.
Angela Weiss | AFP | Getty Images

Beyond Meat on Thursday reported a wider-than-expected loss in the first quarter as restaurant customers take longer to return and grocery shoppers aren’t stockpiling its meat substitutes anymore.

However, CEO Ethan Brown said that the company is seeing a “slow thaw” in the United States and some international markets, prompting the company to issue a revenue forecast for the next quarter.

Shares of the company fell 6% in extended trading.

Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by Refinitiv:

  • Loss per share: 42 cents adjusted vs. 19 cents expected
  • Revenue: $108.2 million vs. $113.7 million expected

Beyond reported fiscal first-quarter net loss of $27.3 million, or 43 cents per share, down from net income of $1.8 million, or 3 cents per share, a year earlier.

Excluding items, the company lost 42 cents per share, wider than the loss of 19 cents per share expected by analysts surveyed by Refinitiv.

This is the third quarter in a row that Beyond has reported a wider-than-expected loss. The company has been investing back into its business as it tries to position itself as a global player. Beyond now has production facilities in China and the Netherlands, for example.

Net sales rose 11.4% to $108.2 million, missing expectations of $113.7 million.

U.S. retail sales jumped by 27.8% during the quarter. Sales in grocery and convenience stores accounted for more than three-quarters of the company’s total U.S. revenue. Prior to the pandemic, retail sales only made up about half of Beyond’s revenue.

Foodservice sales in the United States fell 26% as streamlined menus and less customer traffic at restaurants hurt demand.

For the second quarter, the company is forecasting revenue in the range of $135 million to $150 million, representing an increase of 19% to 32% compared with the year-ago period. Wall Street analysts are expecting net sales of $142.8 million next quarter.

Beyond did not provide an outlook for the full year, citing the uncertainty caused by the pandemic.

You May Also Like

Why Biogen’s Alzheimer’s drug Aduhelm is so controversial

In this article 4523.T-JP BIIB The U.S. Food and Drug Administration’s approval…

Pfizer weight loss pill joins list of obesity drug flops

Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its…

Disney misses on profit and key revenue segments, warns streaming growth could taper

In this article DIS Follow your favorite stocksCREATE FREE ACCOUNT Bob Chapek,…

Disney could soon sell its TV assets as Iger says business ‘may not be core’ to the company

In this article DIS Follow your favorite stocksCREATE FREE ACCOUNT Bob Iger,…